Decitabine plus thalidomide yields more sustained survival rates than decitabine monotherapy for risk-tailored elderly patients with myelodysplastic syndrome-Reference-Cited by-同舟云学术

Decitabine plus thalidomide yields more sustained survival rates than decitabine monotherapy for risk-tailored elderly patients with myelodysplastic syndrome

Published:2015-04 Issue:4 Volume:39 Page:424-428
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Zhao Wei-Hong,Zeng Qing-Chun,Huang Bin-Tao,Li Bing-Sheng,Chen Rui-lin

Funder

National Natural Science Foundation of China

Natural Science Foundation of Inner Mongolia

Inner Mongolia Autonomous Region Health and Family Planning health research projects

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference26 articles.

1. Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome;Ishikawa;Int J Clin Oncol,2014

2. Molecular pathogenesis of myelodysplastic syndromes;Visconte;Transl Med UniSa,2014

3. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B;Silverman;J Clin Oncol,2002

4. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study;Kantarjian;Cancer,2006

5. Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lenalidomide Plus Decitabine Treatment in a Myelodysplastic Syndrome Patient With Deletion 5q and Excess Blasts;Journal of Hematology;2020

2. Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs;Cardiovascular & Hematological Disorders-Drug Targets;2019-01-28

3. Part 5: Myelodysplastic syndromes—Treatment of high-risk disease;Hematology, Transfusion and Cell Therapy;2018-07

4. A comparison of therapeutic dosages of decitabine in treating myelodysplastic syndrome: a meta-analysis;Annals of Hematology;2017-08-25

5. Treatment of Low-Blast Count AML using Hypomethylating Agents;Mediterranean Journal of Hematology and Infectious Diseases;2017-07-01